ADVERTISEMENT

404

Not Found

Is this what you were looking for?

tag big pharma developmental biology immunology

Woman smiling at the camera working out on a blue yoga mat.
Keeping Older Muscles Strong
Hannah Thomasy, PhD, Drug Discovery News | Sep 5, 2023 | 5 min read
From stem cell-recruiting gels to hormone cycle restoration, Tracy Criswell has big ideas about how to combat age-related decline in muscle regeneration.
Guts and Glory
Anna Azvolinsky | Apr 1, 2016 | 9 min read
An open mind and collaborative spirit have taken Hans Clevers on a journey from medicine to developmental biology, gastroenterology, cancer, and stem cells.
An illustration of flowers in the shape of the female reproductive tract
Uterus Transplants Hit the Clinic
Jef Akst | Aug 1, 2021 | 10+ min read
With human research trials resulting in dozens of successful deliveries in the US and abroad, doctors move toward offering the surgery clinically, while working to learn all they can about uterine and transplant biology from the still-rare procedure.
dual expresser t cell immunology type 1 diabetes
The Science News that Shaped 2019
Kerry Grens | Dec 20, 2019 | 6 min read
A T cell discovery, “hachimoji” DNA, a new species of human, and mounting fears of espionage rounded off the list this year.
New Approaches to Discovery Push Research at Big Biotech
James Kling | May 24, 1998 | 6 min read
The biotechnology industry is among the biggest employers of life science professionals, with 140,000 employees generating $17.4 billion of revenue in 1997, according to an industry report by Ernst & Young LLP of Palo Alto, Calif. Since the birth of biotechnology in the 1970s, many of the seminal companies--such as Biogen and Genentech-- have matured into profitable or near- profitable companies. As these companies arose, venture capitalists fell in love with start-up biotechs in the 1980s
Rethinking Lymphatic Development
Amanda B. Keener | Aug 1, 2015 | 9 min read
Four studies identify alternative origins for cells of the developing lymphatic system, challenging the long-standing view that they all come from veins.
Top 10 Innovations 2013
The Scientist | Dec 1, 2013 | 10+ min read
The Scientist’s annual competition uncovered a bonanza of interesting technologies that made their way onto the market and into labs this year.
One Step Beyond: Going Beyond Genomics With Proteomics And Two-Dimensional Gel Technology
Laura Defrancesco | Jan 3, 1999 | 10+ min read
Proteomes and 2D Gel Apparatus Providers Big science has moved on to proteins. With the new brand of science termed proteomics--named by the Australians Marc Wilkins and Keith Williams to mean the "set of PROTEins encoded by the genOME"--the push is on around the globe to produce a complete description of a cell/tissue/organism in terms of the proteins produced. The challenge is all the greater because the expressed protein pattern changes with time and environment--responding to developmenta
Master of the Cell
Judy Lieberman | Apr 1, 2010 | 10+ min read
By Judy Lieberman Master of the Cell RNA interference, with its powerful promise of therapy for many diseases, may also act as a master regulator of most—if not all—cellular processes. RNA silencing. Computer artwork showing a length of RNA (yellow with red rings) bound to an RNA-induced silencing complex (RISC). © Medi-Mation Ltd / Photo Researchers, Inc. ne of the biggest surprises in biology in the past d
How Orphan Drugs Became a Highly Profitable Industry
Diana Kwon | May 1, 2018 | 10+ min read
Government incentives, advances in technology, and an army of patient advocates have spun a successful market—but abuses of the system and exorbitant prices could cause a backlash.

Run a Search

ADVERTISEMENT